Fairmount Funds Management LLC - 10 Nov 2025 Form 3 Insider Report for Galecto, Inc. (GLTO)

Role
Director, 10%+ Owner
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Issuer symbol
GLTO
Transactions as of
10 Nov 2025
Net transactions value
$0
Form type
3
Filing time
17 Nov 2025, 21:48:40 UTC
Previous filing
27 Oct 2025
Next filing
08 Dec 2025
SEC
View on sec.gov

Reporting Owners (5)

Name Relationship Address Signature Signature date CIK
Fairmount Funds Management LLC Director, 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 17 Nov 2025 0001802528
Fairmount Healthcare Fund II L.P. 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P. 17 Nov 2025 0001769651
Fairmount Healthcare Co-Invest V L.P. 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Co-Invest V L.P. 17 Nov 2025 0002091559
Kiselak Tomas 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak 17 Nov 2025 0001830177
Harwin Peter Evan Director, 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Peter Harwin 17 Nov 2025 0001663607

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLTO Series B Preferred Stock 10 Nov 2025 Common Stock 16,366,000 By Fairmount Healthcare Fund II L.P. F1, F2
holding GLTO Series C Preferred Stock 10 Nov 2025 Common Stock 6,957,000 By Fairmount Healthcare Fund II L.P. F2, F3
holding GLTO Series C Preferred Stock 10 Nov 2025 Common Stock 3,478,000 By Fairmount Healthcare Co-Invest V L.P. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Following stockholder approval of the conversion of Series B Preferred Stock into shares of Common Stock, each share of Series B Preferred Stock will be convertible, at the option of the holder, into 1,000 shares of Common Stock, subject to certain limitations. Fairmount (as defined below) may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion.
F2 Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest V L.P. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3 Following stockholder approval of the conversion of Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion.

Remarks:

Exhibit 24 - Power of Attorney Fairmount, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest V L.P. may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.